Whitehawk swoops in for five ADCs via deal with Biocytogen
Whitehawk swoops in for five ADCs via deal with Biocytogen (reported by Fierce Biotech)
Biocytogen
SSE: 688796 ~$1.5B MCAP
Beijing-headquartered global biotechnology company (SSE: 688796, HKEX: 02315) providing integrated antibody drug development solutions through proprietary gene-editing platforms and RenMab/RenNano antibody discovery engines.
Company Info
Upcoming Milestones & Key Dates
2026-Q3
business
Whitehawk $350M+ ADC deal closure expected
2026-Q4
regulatory
Expected IND filings for additional RenMab-discovered antibodies
Clinical Development Pipeline
Multiple RenMab-discovered antibodies
Target: Various (e.g., Claudin 18.2, 4-1BB)Undisclosed
Target: T-cell engager platformRenNano
Target: Nanobody platformRecent News
Leadership Team
Yuelei Shen
Chairman and Chief Executive Officer